Healthcare / BiotechnologyASX
$0.76
+0.03 (+4.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.1M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$0
P/E
N/A
•EV/EBITDA
N/A
•ROE
-52.6%
↓Gross Margin
75.1%
↑Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.6%
FCF CAGR
—
FCF margin
-138.5%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.9M · net income $-10.0M · FCF $-6.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.9M | $4.9M | $8.3M | $2.9M | $4.7M |
| Net Income | $-10.0M | $-10.0M | $-8.2M | $-15.6M | $-16.2M |
| EBITDA | $-10.9M | $-10.9M | $-9.6M | $-17.0M | $-16.6M |
| EPS | -0.02 | -0.02 | -0.02 | -0.04 | -0.04 |
| Gross Margin | 75.1% | 75.1% | 92.4% | 61.9% | 40.7% |
| Operating Margin | -244.3% | -244.3% | -129.7% | -620.5% | -378.3% |
| Net Margin | -203.4% | -203.4% | -98.5% | -532.1% | -345.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.13 | 0.24 | 0.17 |
| Current Ratio | 5.26 | 5.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.8M | $-6.8M | $-7.1M | $-14.2M | $-14.0M |
| Returns | |||||
| ROE | -52.6% | -52.6% | -29.0% | -44.9% | -33.4% |
| Valuation | |||||
| P/B | 16.58 | 16.58 | 1.45 | 3.76 | 5.84 |
| Growth & Yield | |||||
| Revenue Growth | -40.7% | -40.7% | 182.0% | -37.2% | — |
| EPS Growth | -19.5% | -19.5% | 50.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+703.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.02
Residual
+703.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.